Treatment for Hepatitis B

Similar documents
Treatment for Hepatitis B

Hepatitis C: Ribavirin/Pegylated Interferon combination therapy

Management of Hepatitis B - Information for primary care providers

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Chronic hepatitis B virus (HBV)

The facts you need to know

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Intron A Hepatitis B. Intron A (interferon alfa-2b) Description

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

You have been diagnosed with chronic hepatitis C. I I

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

People with bleeding disorders and hepatitis C

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

Update on Hepatitis B and Hepatitis C

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Factsheet: Treatments for hepatitis C Direct Acting Antivirals (DAAs)

Scottish Medicines Consortium

Chronic hepatitis B: diagnosis, monitoring and management

HIV and women having children

EAST LONDON INTEGRATED CARE

TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II)

Treatment Op+ons for Chronic Hepa++s B. Judith Feinberg, MD Project ECHO Jan. 19, 2017

Factsheet: New Treatments for hepatitis C Direct Acting Antivirals (DAAs)

Hepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019

Chronic hepatitis B. A clinical audit of GP management. Hepatitis B virus (HBV) infection represents a growing health burden

ACTIVITY DISCLAIMER. Kurt Cook, MD, MSc DISCLOSURE. Audience Engagement System. Learning Objectives

HEPATITIS B MANAGEMENT

Chronic Hepatitis B: management update.

Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018

29th Viral Hepatitis Prevention Board Meeting

Scottish Medicines Consortium

Management of Chronic Hepatitis B in Asian Americans

casebasedhepatitis bmanagement Management of Hepatitis B: A Case-based Approach

Hepatitis B infection

Monitoring Hepatitis C

Welcome to the Hepatitis C Education Class

Hepatitis B screening and surveillance in primary care

Short title: BENEFIT STUDY, STUDY REPORT (ML25614) Synopsis/Abstract

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology

Hepatitis B Treatment Pearls. Agenda

Cornerstones of Hepatitis B: Past, Present and Future

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Abnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a

entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd

X-Plain Hepatitis B Reference Summary

ABCs of Viral Hepatitis What Primary Care Physicians Need to Know

HEPATITIS C TREATMENT GUIDANCE

Chronic Hepatitis C. Risk Factors

Hepatitis B Prior Authorization Policy

Pegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17

Arm yourself against Hep B! Vaccinate

Information about. Hepatitis C. What is Hepatitis C? Who should be tested for Hepatitis C?

Horizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007

HEPATITIS HEPATITIS A. The Hepatitis Alphabet HOW DOES ONE GET HEPATITIS A? THE SYMPTOMS of HEPATITIS A

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Hepatitis B and D Update on clinical aspects

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST

Clinical Presentation of Viral Hepatitis 1-The symptoms of acute viral hepatitis caused by HAV, HBV, HCV, HDV, and HEV are similar (3).

Therapeutic Guidelines on Management of Chronic Hepatitis B in Asia

Pegylated Interferons and Ribavirins

Drug Class Monograph

Hepatitis C SYMPTOMS COMPLICATIONS

2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B

Management of Patients with Chronic Hepatitis B: The Alaska Experience

Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection

Viral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician

HBV in HIV Forgotten but not Gone

Entecavir for the treatment of chronic hepatitis B infection

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Investigation into withdrawal of entecavir after 20 months in an HBsAb-positive patient who received HBsAg allogeneic stem cell transplantation

Objectives. Five Take Home Pearls. We Can Cure Hepatitis C. Hepatitis C Screening, Treatment and the Family Physician 10/15/2018

Chronic Hepatitis B Infection

Management of Hepatitis B

Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17

Viral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH

Viral Hepatitis Diagnosis and Management

Need for long-term evaluation of therapy in Chronic Hepatitis B

ESCMID Online Lecture Library. by author

Module 1 Introduction of hepatitis

Notes Testing: Follow Up and Giving Results

Hepatitis C Management and Treatment

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

Hepatitis C. Request a Test. Benefits of testing in AOD services to improve treatment uptake

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

IMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C

MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman

Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

ARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update

Chronic Hepatitis. Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

Exploring the risks of liver cancer after successful treatment for hepatitis C virus

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17

Transcription:

Introduction This Fact Sheet is for people with chronic hepatitis B (CHB) who need treatment. Chronic hepatitis B is diagnosed by a positive hepatitis B surface antigen (HBsAg) which has been present for more than 6 months. It is important to understand that NOT all people with CHB need treatment. Please read on to find out why some people need to start treatment and what treatment for hepatitis B entails. Hepatitis B disease progression As hepatitis B replicates in liver cells (hepatocytes) it sets up a cycle of inflammation, injury and repair. Over time this inflammatory cycle can lead to scarring of the liver, known as fibrosis. If left untreated, chronic replication of hepatitis B can progress to cirrhosis, decompensated liver disease (liver failure) and liver cancer (known as hepatocellular carcinoma or HCC). Disease progression is thought to be strongly linked to high levels of hepatitis B virus. Other factors associated with disease progression include: Presence of hepatitis B e antigen (detected on a blood test) Older age (possibly related to a longer period of infection) High alcohol consumption Co-infection with hepatitis C or HIV Cigarette smoking Male gender Suppressing the amount of hepatitis B DNA and slowing down disease progression is the goal of hepatitis B treatment. Page 1

What do the blood tests mean? Australian Guidelines recommend that the all people with chronic hepatitis B have regular 6 monthly blood tests to measure liver function. People with CHB have access to one funded hepatitis B viral load per year. Abnormal or elevated results indicate that liver damage is occurring and treatment may be required. If this is the case a referral will be made to a liver specialist, such as a gastroenterologist or infectious diseases physician, to talk about what is involved with starting treatment To determine whether treatment for hepatitis B is needed a number of blood tests and in some cases a liver Fibroscan maybe required. Some of the blood tests include: Viral load or Hepatitis B DNA level Hepatitis B DNA is the genetic material of the hepatitis B virus - also known as hepatitis B viral load. A DNA test measures the amount of virus found in the blood. If the result is low it generally indicates that the virus is being controlled by the immune system. A high result shows that the virus is active and multiplying in the liver. Successful treatment would show a fall in DNA levels corresponding with decreased viral activity in the liver. Hepatitis B e-antigen A hepatitis B e antigen (HBeAg) is a viral protein that is produced by hepatitis B infected cells. If the HBeAg test is positive it indicates a high level of viral activity and increased infectiousness. If the result is negative it indicates less viral replication and less infectiousness. Some people have a mutant strain of hepatitis B which means that they are HBeAg negative but have high levels of hepatitis B DNA. The aim of hepatitis B treatment is suppress the virus and support the immune system to convert HBeAg to HBeAb. Hepatitis B e-antibody A hepatitis B e antibody (HBeAb) is produced by the immune system of some people in response to the HBeAg. People needing hepatitis B treatment will initially have a negative HBeAb. If treatment is successful, the HBeAb will become positive. The purpose of treating some people with CHB is to convert HBeAg positive to negative and HBeAb from negative to positive. However, some people who are HBeAb positive may require lifelong treatment because they are already in this state. Page 2

Liver function tests Liver function tests (LFTs) also known as liver enzymes - assess the general health of the liver. The most important enzyme in the LFT is the ALT (alanine aminotransferase). This ALT is found inside liver cells and can leak into the bloodstream when the liver is injured. If the ALT is high this indicates liver inflammation. Alphafeto-protein Alphafeto-protein (AFP) is a protein normally found in blood. High levels of AFP are associated with cell growth and may indicate the presence of a liver cancer. This test is done routinely, every 6 months, for all people with chronic hepatitis B at risk of developing liver cancer. Other investigations Fibroscan Fibroscan technology, which is similar to an ultrasound, allows for the non-invasive assessment of liver fibrosis or scarring by measuring liver stiffness. Liver biopsy Liver biopsy maybe required as a diagnostic method to further assess level of liver damage and progression. What are current medical treatments and what do they do? The aim of hepatitis B treatment is to reduce the amount of hepatitis B virus in the liver which helps to prevent liver damage and reduce the risk of developing cirrhosis, liver failure and liver cancer. It is rare that hepatitis B treatment will result in a cure and this only occurs in approximately 3-8% of patients. There are 3 drugs used in Australia as first line therapy to treatment of hepatitis B including 1 injectable medication (pegylated interferon) and 2 oral medications (Entecavir and Tenofovir). The type of treatment prescribed will depend on the results of blood tests. Page 3

Oral medications The 2 first line oral medications for hepatitis B treatment (entacevir, tenofovir,) are highly effective against hepatitis B. These are oral tablets taken once a day, long term. There a few side effects associated with their use. Pegylated interferon Pegylated interferon (peginterferon) is given as an injection under the skin once a week for 48 weeks. Patients are taught to give the injection to themselves at home. Interferon is a protein naturally produced in the body to fight viruses by boosting the immune system. The medication is a synthetic reproduction of the naturally produced Interferon. Interferon boosts the body s own immune response and reduces hepatitis B replication. Pegylated interferon is used to treatment CHB in specific circumstances such as women of childbearing age, where a defined period of 48 weeks of treatment is required. Women with a high ALT and low HBV DNA do the best on pegylated interferon. About 35% of people with CHB who have Peginterferon achieve long term benefit with their HBeAg going from positive to negative and their HBeAb becoming positive. Side effects of pegylated interferon The most common side effect is flu-like symptoms including fever, sweats, muscle/ joint pain and headaches. These symptoms are usually worse at the beginning, and may go away during treatment. Usually simple pain relief like paracetamol (Panadol) will help. Depression and mood changes are another common side effect. These can occur in people who have not had any previous history of depression. Support from a counsellor or antidepressant medication may be recommended. Other side effects include changes in blood cell counts, hair loss or thinning, thyroid problems and weight loss. Most of these will go away after the treatment is stopped. Page 4

Due to the side effects, it is very important that people who are having Peginterferon treatment attend clinic appointments and have regular blood tests. Sometimes the dose of Peginterferon has to be lowered, or treatment stopped for a short time, until the blood tests return to normal or the side effects are reduced. For more information on individual treatment see below: Contacts HIV, Hepatitis & STI Education + Resource Centre Education and information for the Victorian community 03 9076 6993 http://www.hivhepsti.info/ Hepatitis Victoria Hepatitis hotline 1800 703 003 http://www.hepcvic.org.au/ Hepatitis Australia Hepatitis B health promotion 02 6232 4257 http://www.hepatitisaustralia.com/ HIV and Hepatitis.com International site with detailed information http://www.hivandhepatitis.com/hepatitis-b Liver/hepatitis clinics in Victoria These are the specialist liver or hepatitis clinics in Victoria. Contact the clinics for information on making an appointment. Ask for the Liver or Hepatitis Clinic. You will need a referral from your GP. METROPOLITAN MELBOURNE Public Alfred Hospital, Prahran (03) 9076 2223 Austin/Repatriation Medical Centre, Heidelberg (03) 9496 3498 Bayside Gastroenterology, Moorabbin (03) 9553 0060 Monash Medical Centre, Clayton (03) 9594 5545 Page 5

Northern Hospital, Epping (03) 84058335 Royal Children s Hospital, Parkville, Liver Diseases Clinic (03) 9345 6180 Royal Melbourne Hospital, Parkville (03)9342 7212 Springvale Community Health - (Monash Medical Centre) (Appointments via Monash clinic) (03) 9594 5545 St. Vincent s Hospital, Fitzroy (03) 9288 3580 Western Hospital, Footscray (03) 83456490 Private Box Hill Hospital (03) 9895 3353 Cabrini Private Hospital, East Malvern (03) 9508 1862 (Melbourne Gastrointestinal Investigations Unit) Ringwood East, Maroondah Hospital Liver Clinic (03) 9871 3333 REGIONAL Public Ballarat Base Hospital Liver Clinic (Mair Street) (03) 5202 4444 Geelong Liver Clinic (03) 5226 7254 Produced by Education + Resource Centre (HIV, Hepatitis, STIs), March 2003 Last Reviewed June 2013 Acknowledgement and special thanks to: All those who gave generously of their time, energy and experience to help develop and review this Fact Sheet. Disclaimer This site, or any information you may access via it, is not intended to replace professional health care advice. We strongly recommend that you discuss any issues concerning your health and treatment with your health care provider before taking action or relying on the information. We do not evaluate or screen WWW sites on the basis of accuracy and therefore we do not assume liability for any information obtained from these sites. If the credibility of the information is important to you, we suggest that you follow some steps to evaluate the site critically. Page 6